Sincere Capital
VC Fund
Shanghai, China
Sincere Capital is a VC fund in Shanghai focused on Biotechnology and Pharmaceutical. Sincere Capital, which was founded by senior investment specialists and had completed all the necessary regulatory registration procedures with Asset Management Association of China, mainly engages in investing in the fields of technology innovation and State-Owned Enterprises (SOE) reforms.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 27%
Last updated:
For AI agents: llms.txt
Industries Sincere Capital invests in
Stages Sincere Capital invests in
Countries Sincere Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Series A
- $14M–$279M
- Series B
- $15M–$30M
Investment Focus
Industry
- Biotechnology 5 (33%)
- Pharmaceutical 4 (27%)
- Medical 3 (20%)
- Biopharma 3 (20%)
- Electronics 3 (20%)
Stage
- Series A 6 (40%)
- Series B 3 (20%)
- Seed 2 (13%)
- Series C 2 (13%)
- Angel 1 (7%)
Country
- China 13 (87%)
- United States 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Youjin Lan
Chief Executive Officer
|
Chief Executive Officer | Total investments: 1 | Find email | |
|
Chen Xi
Executive General Manager
|
Executive General Manager | Total investments: 1 | Find email | |
|
Huang Weiting
Partner
|
Partner | Total investments: 1 | Find email | |
|
Lan Youjin
Managing partner
|
Managing partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Yoguang Technology
|
Seetrum is an electronics manufacturing firm that provides advanced spectroscopy chips, AI algorithms, and smart perception solutions. | $14.7M / Series A / Jun 23, 2026 | |
XellSmart
|
Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments. Xellsmart is located in Minhang District, Shanghai, China. | $72.6M / Series C / Apr 01, 2026 | |
Spectral Domain Technology
|
Spectral Domain Technology is a provider of 5G low-orbit broadband terminals, supplying operators, industrial Internet companies, satellite Internet, and government and enterprise customers with ocean communication needs. | Series A / Sep 27, 2024 | |
Laser Link
|
Laser Link is a laser communication company that focuses on the development of precision optical-mechanical products for commercial aircraft. | $13.7M / Series A / Nov 10, 2023 | |
Zenosic
|
Zenosic focuses in the design and R&D of high-performance network chips, along with offering leading chip products for cloud service providers, equipment makers, operators, and diverse industries. | $41.9M / Series A / Sep 06, 2023 | |
Cullgen
|
Cullgen is a drug discovery service intended to create new drugs for the treatment of diseases that currently lack effective therapies. The company's services use protein degradation technology that focuses on the selective degradation of disease-causing proteins, a novel treatment for cancer, inflammatory and autoimmune diseases, includingtargets previously considered undruggable, enabling scientists with new means to develop novel therapeutic approaches for various diseases. | $35M / Series C / May 08, 2023 | |
Base Therapeutics
|
Best Bio is a developer of cell therapy products and gene therapy products. | Series A / Jan 16, 2023 | |
GalaxySpace
|
GalaxySpace is a commercial micro-satellites developer. | Series D / Sep 07, 2022 | |
Bichen Pharmaceutical
|
Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases. | $30M / Series B / Jan 04, 2022 | |
|
Yoguang Technology
|
Seetrum is an electronics manufacturing firm that provides advanced spectroscopy chips, AI algorithms, and smart perception solutions. | Seed / Dec 29, 2021 | |
| See all 15 investments → | |||
Co-Investors
Baidu Ventures
2 deals together
Highlight Capital
2 deals together
CCB International
1 deal together
Chaos Investment
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sincere Capital invest in?
Sincere Capital invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series A and Series B stage. Most of the 15 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sincere Capital's check size?
Sincere Capital typically joins rounds of $14M–$279M at Series A and $15M–$30M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sincere Capital participates in.
How do I contact Sincere Capital?
Public channels for Sincere Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sincere Capital?
The team at Sincere Capital includes Youjin Lan (Chief Executive Officer), Chen Xi (Executive General Manager) and Huang Weiting (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
